Skip to Content

Hexaminolevulinate Disease Interactions

There are 3 disease interactions with hexaminolevulinate:

Major

Hexaminolevulinate (applies to hexaminolevulinate) cystitis

Major Potential Hazard, High plausibility.

Inflammation of the bladder may interfere with the diagnostic utility of hexaminolevulinate, which is an ester of the heme precursor, aminolevulinic acid. Following intravesical instillation of hexaminolevulinate, photoactive porphyrins are formed and accumulate intracellularly in bladder wall lesions. In humans, a higher degree of accumulation of porphyrins has been demonstrated in neoplastic or inflamed cells compared to normal bladder urothelium. As such, inflammation may lead to increased porphyrin buildup and higher risk of local toxicity upon illumination as well as false-positive fluorescence. Hexaminolevulinate should not be used in patients at high risk of bladder inflammation, such as those who received BCG immunotherapy or intravesical chemotherapy within the past 90 days. Widespread inflammation of the bladder should be excluded by cystoscopy before hexaminolevulinate is administered. If a widespread inflammation in the bladder becomes evident during white light inspection, the blue light inspection should be avoided.

Major

Hexaminolevulinate (applies to hexaminolevulinate) hematuria

Major Potential Hazard, High plausibility.

The use of hexaminolevulinate is contraindicated in patients with gross hematuria. The presence of blood within the bladder may interfere with the detection of tissue fluorescence.

Major

Hexaminolevulinate (applies to hexaminolevulinate) porphyria

Major Potential Hazard, High plausibility.

The use of hexaminolevulinate is contraindicated in patients with a diagnosis or a family history of porphyria. Hexaminolevulinate is an ester of the heme precursor, aminolevulinic acid. Following intravesical instillation, photoactive porphyrins are formed and accumulate intracellularly in bladder wall lesions.

Hexaminolevulinate drug interactions

There are 2 drug interactions with hexaminolevulinate

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.